|Day Low/High||34.22 / 36.02|
|52 Wk Low/High||8.00 / 41.97|
If you aren't positioned long already, you are struggling with what to do here.
This is one of those days when it may pay to walk away.
Sarepta Therapeutics, Bellicum Pharmaceuticals and Novavax were among the biotech stock movers in premarket trading on Wednesday.
Keep an eye on the pattern of morning weakness and afternoon strength.
After yesterday's surprise pullback, this is the sort of consolidation we need.
Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sarepta Therapeutics Inc , where a total of 14,285 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 60.3% of SRPT's average daily trading volume over the past month of 2.4 million shares.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on February 28, 2017, that were previously approved by the Compensation Committee of...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today...
Here's how to rake in the profits off some potential big breakouts.
If you play strong defense, be prepared to change course very quickly.
But it is all about timing, and so far there is no indication that this extended market is about to turn.
It will be interesting to see today if afternoon strength occurs once again.
Gilead (finally!) has acquired something from Sarepta, even if it is quite small.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review...
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.